top of page

Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy

Prioritisation of screening programs for spinal muscular atrophy (SMA) will ensure early diagnosis across Canada and bring lasting impact to babies and caregivers


Novartis celebrates Canada-wide implementation of newborn screening for spinal muscular atrophy

Novartis Pharmaceuticals Canada Inc. (Novartis) applauds the work done by Muscular Dystrophy Canada and the provinces to ensure that every newborn in Canada will be screened to detect spinal muscular atrophy (SMA). 


As of today, all provinces and territories have implemented newborn screening programs for SMA. With these programs in place, a blood test routinely done shortly after birth will be able to detect SMA before symptoms appear. This is a significant advancement for this rare, often debilitating genetic disease, which for some babies can be life-threatening. Novartis is pleased to have contributed to this shift in policy across the country through a multi-year multi-phase collaboration with Muscular Dystrophy Canada.


"Effective implementation of policy change on this scale is only possible when key stakeholders collaborate openly towards a common vision. We are thankful for the partnership which led to the vital shift that will identify babies with SMA at birth," said Stacey Lintern, CEO, Muscular Dystrophy Canada. "We are most proud that the opportunity for early detection of SMA is now equitably offered to all newborns across the country."


Early diagnosis to treat SMA quickly is crucial to stopping progression of the disease and gives these babies the opportunity to reach more advanced motor milestones like walking.


"We couldn't be prouder to support the implementation of newborn screening for SMA for all Canadian babies. This positive progress is in large part thanks to the commitment and leadership of Muscular Dystrophy Canada whose determination has fundamentally changed the course of an SMA diagnosis in this country," said Mark Vineis, Country President for Novartis Canada. "Being able to identify and treat SMA in a timely manner brings hope and the possibility for patients to have better outcomes. For many families this will be life altering."


In Canada each year one in 6,000 to 10,000 babies are born with SMA, a rare, genetic neuromuscular disease caused by a defective or missing SMN1 gene. The most severe form of the disease (Type 1) constitutes approximately 60% of all SMA at birth or 21 cases per year in Canada. Without a functional SMN1 gene, infants with SMA gradually lose motor neurons responsible for muscle functions such as breathing, swallowing, speaking and walking.


About Novartis

Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.


In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country.


Reach out to us at PR Desk 

Read more on our ​Partner sites: Dais World | Growth Reports Business

Get rewarded for your reading habits on the Dais World app!

The Progress Catalyst

TPC3_edited.jpg

Throughout history, there have been individuals who have made a profound impact on the world. These individuals have pushed the boundaries of what is possible, and have made the world a better place for all. We will keep exploring the lives and work of these progress catalysts, and show how their contributions have shaped the world we live in today.

 

The Progress Catalyst is a celebration of these individuals. It is a tribute to their courage, their vision, and their determination. It is a reminder that we all have the power to make a difference in the world.

Posts Archive

Tags

bottom of page